Exicure (XCUR) announced it has completed patient enrollment in its ongoing Phase 2 clinical trial evaluating the safety and efficacy of GPC-100 in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XCUR: